Adjuvant chemotherapy for locally advanced urothelial carcinoma: An overview of the USC experience

World Journal of Urology

Volumn 27, Issue 1, 2009, Pages 39-44

  Dorff, Tanya B ^a,b   Tsao Wei, Denice ^b   Miranda, Gus ^b   Skinner, Donald G ^a   Stein, John P ^a   Quinn, David I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Bladder cancer; Chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; DRUG DERIVATIVE; GEMCITABINE; M VAC PROTOCOL; M-VAC PROTOCOL; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER TUMOR; DISEASE COURSE; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; UNITED STATES; UNIVERSITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALIFORNIA; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNIVERSITIES; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 59249101131     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0342-4     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, THun MJ (2008) Cancer statistics 2008. CA Cancer J Clin 58:71-96. doi: 10.3322/CA.2007.0010
2. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, Skinner E, Bochner B, Thangathurai D, Mihail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666-675
3. Ruggeri EM, Giannarelli D, Bria E, Carlini P, Felici A, Nelli F, Gallucci M, Cognetti F, Pollera CF (2006) Adjuvant chemotherapy in muscle-invasive bladder cancer: A pooled analysis from phase III studies. Cancer 106:783-788. doi: 10.1002/cncr.21676
4. Grossman HB, Natale R, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarsody MF, Wood DP Jr, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866. doi: 10.1056/NEJMoa022148
5. Logothetis C, Swanson D, Amato R, Banks M, Finn L, Ayala A, Ro J, Babaian R, Dinney C, Ellerhorst J, Hall C, von Eschenbach A (1996) Optimal delivery of perioperative chemotherapy: Preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 155:1241-1245. doi: 10.1016/S0022-5347(01)66230-X
6. Millikan R, Dinney C, Swanson D et al (2001) Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19(20):4005-4013
7. Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64(12):2448-2458. doi:10.1002/ 1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7
8. Sternberg CN, Yagoda A, Scher HI et al (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139(3):461-469
9. Sternberg CN, Yagoda A, Scher HI et al (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133(3):403-407
10. Moore MJ, Winquist EW, Murray N et al (1999) Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17(9):2876-2881
11. Von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068-3077
12. Skinner DG, Daniels JR, Russell CA et al (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 145:459-464
13. Kassouf W, Agarwal PK, Herr HW et al (2008) Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: Analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26:121-126. doi: 10.1200/ JCO.2007.12.9247
14. Stein JP, Cai J, Groshen S, Skinner DG (2003) Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: Concept of lymph node density. J Urol 170:35-41. doi: 10.1097/01.ju.0000072422.69286.0e
15. Sternberg CN, de Mulder P, Schornagel JH et al (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50-54. doi: 10.1016/j.ejca.2005.08.032
16. Kim SO, Jeong JY, Kim MR et al (2008) Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 14:3083-3088. doi: 10.1158/1078-0432.CCR-07-4591
17. Lord RV, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291
18. Olaussen K, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991. doi: 10.1056/NEJMoa060570
19. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11:2625-2636. doi: 10.1158/ 1078-0432.CCR-04-1988